Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized controlled study of azelastine-based comprehensive treatment for proliferative allergic conjunctivitis
ChiCTR1900022169Phase 4Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jul 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus, fluorometholone and azelastine in allergic conjunctivitis (AC) (4 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Grading of palpebral conjunctiva papilla at 6 weeks, Grading of bulbar conjunctiva lesions at 6 weeks and 2 more. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
tacrolimusfluorometholoneazelastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on ChiCTR1900022169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022169.